Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Supriya Lifescience Ltd. Share Price
Day's Range
Day's Range
Low
₹686.05
High
₹719.65
Price Summary
| Previous Close | ₹686.85 |
|---|---|
| Day's Range | ₹686.05 - ₹719.65 |
| Open | ₹710.75 |
| 52 Week Range | ₹545.50 - ₹832.40 |
| Volume | 1,26,058 |
| Market Cap | ₹0.01 |
| Previous Close | ₹686.60 |
|---|---|
| Day's Range | ₹686.40 - ₹720.60 |
| Open | ₹716.35 |
| 52 Week Range | ₹545.65 - ₹831.00 |
| Volume | 7,318 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 865.83 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.14 |
| Price/Earning (TTM) | 31.17 |
| TTM EPS (₹) | 23.02 |
| P/E Ratio | 31.41 |
| Book Value(₹) | 5.10 |
| PAT Margin (%) | 24.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 27.63 |
| Trade Value ( ₹ in Lacs) | 50.25 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.14 |
| Price/Earning (TTM) | 31.17 |
| TTM EPS (₹) | 23.02 |
| P/E Ratio | 31.41 |
| Book Value(₹) | 5.10 |
| PAT Margin (%) | 24.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 27.63 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1856.48 | 5703.4 |
| Expenses | N/A | N/A |
| PBT | 625.8 | 1656.9 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 467.83 | 1191.14 |
About Supriya Lifescience Ltd.
| Founded | 2008 |
|---|---|
| Managing Director | Saloni Satish Wagh |
| NSE Symbol | SUPRIYA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,49,251.48 | 1,862.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,242.24 | 6,681.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,951.96 | 4,413.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,191.66 | 8,018.65 | 6,696.50 - 6,696.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,811.05 | 1,281.00 | 1,143.90 - 1,143.90 |
| Cipla Ltd. | 1,05,391.40 | 1,302.20 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,02,674.68 | 2,269.55 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,937.63 | 2,414.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,01,003.24 | 1,028.75 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 96,261.37 | 938.35 | 835.50 - 835.50 |
No Records Found
Latest News
Supriya Lifescience informs about updates
Supriya Lifescience informs about transcript of earnings Call
Further to its Letters dated February 04, 2026, February 09, 2026, and February 10, 2026, Supriya Lifescience has informed that the Transcript of the Earnings Call held on February 10, 2026, with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025, is available on the Company's website at: https://www.supriyalifescience.com/ir-financial.php.
The above information is a part of company’s filings submitted to BSE.
Viyash Scientific informs about board meeting
Bharat Parenterals informs about earnings call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bharat Parenterals has informed that the Earnings Conference Call to discuss operational and financial performance of the Company for the quarter and Year ended on March 31, 2026 is scheduled to be held on Tuesday, May 19, 2026 at 03:00 pm (I.S.T.). The Invitation for the Q4FY26 Earnings Conference Call is annexed.
The above information is a part of company’s filings submitted to BSE.
Asarfi Hospital Ltd. - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 450.35 | 351.04 | 28.29 | 1731.97 | 1217.78 | 42.22 | 1731.97 | 1217.78 | 42.22 |
| Other Income | 6.65 | 36.57 | -81.82 | 27.85 | 63.57 | -56.19 | 27.85 | 63.57 | -56.19 |
| PBIDT | 85.21 | 101.13 | -15.74 | 382.95 | 314.14 | 21.90 | 382.95 | 314.14 | 21.90 |
| Interest | 7.05 | 13.48 | -47.70 | 42.44 | 40.81 | 3.99 | 42.44 | 40.81 | 3.99 |
| PBDT | 78.16 | 87.65 | -10.83 | 340.51 | 273.33 | 24.58 | 340.51 | 273.33 | 24.58 |
| Depreciation | 27.43 | 32.30 | -15.08 | 114.42 | 126.17 | -9.31 | 114.42 | 126.17 | -9.31 |
| PBT | 50.73 | 55.35 | -8.35 | 226.09 | 147.16 | 53.64 | 226.09 | 147.16 | 53.64 |
| TAX | 9.82 | 17.07 | -42.47 | 55.33 | 37.36 | 48.10 | 55.33 | 37.36 | 48.10 |
| Deferred Tax | -5.84 | 2.66 | -319.55 | -3.47 | 6.55 | -152.98 | -3.47 | 6.55 | -152.98 |
| PAT | 40.91 | 38.28 | 6.87 | 170.76 | 109.80 | 55.52 | 170.76 | 109.80 | 55.52 |
| Equity | 196.77 | 196.77 | 0.00 | 196.77 | 196.77 | 0.00 | 196.77 | 196.77 | 0.00 |
| PBIDTM(%) | 18.92 | 28.81 | -34.32 | 22.11 | 25.80 | -14.29 | 22.11 | 25.80 | -14.29 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Supriya Lifescience Ltd. is ₹686.85 as of 2026-05-12.
The market capitalisation of Supriya Lifescience Ltd. is ₹5,775.04 as of 2026-05-11.
The 1-year return of Supriya Lifescience Ltd. is -31.20% as of 2026-05-12.
The P/E ratio of Supriya Lifescience Ltd. is 31.41 as of 2026-05-12.
The 52-week high and low of Supriya Lifescience Ltd. are ₹832.40 and ₹545.50, respectively, as of 2026-05-12.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
